This is a translation of the Swedish version of the notice convening the extraordinary general meeting. When in doubt, the Swedish wording prevails.

Notice of extraordinary general meeting in SURGICAL SCIENCE SWEDEN AB (publ)

Surgical Science Sweden AB (publ), Reg. No. 556544-8783, with its registered office in Gothenburg, gives notice of the extraordinary general meeting to be held on December 11, 2026, at 10:00 a.m. at the company's premises at Drakegatan 7A in Gothenburg. Registration starts at 09:45 a.m.

Right to participate in the extraordinary general meeting and notice of participation

Participation in the extraordinary general meeting at the venue

A shareholder who wishes to participate in the extraordinary general meeting at the venue in person or represented by a proxy must (i) be recorded as a shareholder in the share register maintained by Euroclear Sweden AB relating to the circumstances on December 3, 2026, and (ii) no later than December 7, 2026 give notice by post to Surgical Science Sweden AB (publ), att: Hannah Lindgren, Drakegatan 7A, SE-412 50 Gothenburg, Sweden, or via e-mail to agm@surgicalscience.com. When providing such notice, the shareholder shall state name, personal or corporate registration number, address, telephone number and the number of any accompanying assistant(s) (maximum two assistants) as well as information about any proxy.

If a shareholder is represented by proxy, a written, dated proxy for the representative must be issued. A proxy form is available on the company's website, www.surgicalscience.com. If the proxy is issued by a legal entity, a certificate of registration or equivalent certificate of authority should be enclosed. To facilitate the registration at the general meeting, the proxy and the certificate of registration or equivalent certificate of authority should be sent to Surgical Science Sweden AB as set out above so that it is received no later than December 10, 2026.

Participation by advance voting

A shareholder who wishes to participate in the extraordinary general meeting by advance voting must (i) be recorded as a shareholder in the share register maintained by Euroclear Sweden AB relating to the circumstances on December 3, 2026, and (ii) give notice no later than December 7, 2026 by casting its advance vote in accordance with the instructions below so that the advance vote is received by Surgical Science Sweden AB no later than on that day.

A shareholder who wishes to participate in the extraordinary general meeting at the venue in person or represented by a proxy must give notice thereof in accordance with what is set out under *Participation in the extraordinary general meeting at the venue* above. This means that a notification by advance vote is not sufficient for a person who wishes to participate at the venue.

A special form shall be used when advance voting. The advance voting form is available on the company's website www.surgicalscience.com. A completed and signed form may be submitted by post to Surgical Science Sweden AB (publ), att: Hannah Lindgren, Drakegatan 7A, SE-412 50 Gothenburg, Sweden or via e-mail to agm@surgicalscience.com. The completed form shall be received by Surgical Science Sweden AB no later than December 7, 2026. The shareholder may not provide special instructions or conditions in the voting form. If so, the vote (i.e. the advance vote in its entirety) is invalid. Further instructions and conditions are included in the form for advance voting.

If a shareholder votes by proxy, a written and dated proxy shall be enclosed to the advance voting form. A proxy form is available on the company's website www.surgicalscience.com. If the shareholder is a legal entity, a certificate of registration or equivalent certificate of authority should be enclosed. If a shareholder has voted in advance and then attends the extraordinary general meeting in person or through a proxy, the advance vote is still valid except to the extent the shareholder participates in a voting procedure at the general meeting or otherwise withdraws its casted advance vote. If the shareholder chooses to participate in a voting at the general meeting, the vote cast will replace the advance vote with regard to the relevant item on the agenda.

Nominee-registered shares

To be entitled to participate in the extraordinary general meeting, a shareholder whose shares are held in the name of a nominee must, in addition to providing notification of participation, register its shares in its own name so that the shareholder is recorded in the share register relating to the circumstances on December 3, 2026. Such registration may be temporary (so-called voting right registration) and is requested from the nominee in accordance with the nominee's procedures and in such time in advance as the nominee determines. Voting right registrations completed by the nominee no later than December 7, 2026, are taken into account when preparing the share register.

Agenda

1. Opening of the extraordinary general meeting.
2. Election of chairman of the extraordinary general meeting.
3. Preparation and approval of the voting list.
4. Approval of the agenda.
5. Election of one or two persons who shall approve the minutes.
6. Determination of whether the extraordinary general meeting has been duly convened.
7. Resolution on authorisation for the board of directors to resolve on the acquisition and transfer of own shares.
8. Closing of the extraordinary general meeting.

Election of chairman of the extraordinary general meeting (item 2)
The board of directors proposes that the chairman of the board of directors, Gisli Hennermark, or the person appointed by the board of directors in his absence, be elected chairman of the extraordinary general meeting.

Resolution on authorisation for the board of directors to resolve on the acquisition and transfer of own shares (item 7)
The board of directors proposes that the extraordinary general meeting authorises the board of directors, for the period until the end of the next annual general meeting, on one or more occasions, to resolve on the acquisition of own shares. Acquisitions may be made of such a number of shares that Surgical Science Sweden AB (publ) holds no more than one-tenth of all outstanding shares in the company. Acquisitions may be made on Nasdaq First North Growth Market, and shall be carried out at a price per share not exceeding the higher of the prices for the last independent trade and the highest current independent purchase bid on Nasdaq First North Growth Market, and not at a price lower than the lowest price at which an independent purchase can be made, and shall otherwise be carried out in accordance with the rules of Nasdaq First North Growth Market. Payment for the shares shall be made in cash.

Furthermore, the board of directors proposes that the extraordinary general meeting authorises the board of directors, for the period until the end of the next annual general meeting, on one or more occasions, to resolve on the transfer of own shares. Transfers may take place on Nasdaq First North Growth Market at a price within the price range registered on Nasdaq First North Growth Market at any given time, meaning the range between the highest purchase price and the lowest sale price. Transfers may also be made in other ways, with or without preferential rights for the shareholders, against cash payment or against payment through set-off or in kind, or otherwise on special conditions. In the case of transfers other than on Nasdaq First North Growth Market, the price shall be established so that it is on market terms. The transfer of own shares may be made of up to such number of shares as is held by the company at the time of the board of directors' resolution regarding the transfer.

The board of directors may only exercise these authorisations to the extent that the acquisition or transfer of own shares is permitted under applicable law, market abuse rules and the applicable regulations of the market where the company's shares are listed.

The purpose of the proposed authorisations to repurchase and transfer own shares is to enable the board of directors to adapt the company's capital structure to its capital needs and, in doing so, to be able, amongst other things, to use the acquired shares as a means of payment in the acquisition of assets or rights.

The board of directors, or the individual it appoints, shall otherwise be entitled to amend the above decision as may prove necessary in connection with its registration and otherwise take the measures necessary to implement the decision.

Should the extraordinary general meeting resolve in accordance with the board of directors' proposal, the new authorisation will replace the authorisation regarding the acquisition and transfer of own shares resolved upon by the annual general meeting on May 21, 2026. The background is that the previous authorisation was resolved upon before the new rules, which enable public limited liability companies to acquire and transfer own shares on MTF platforms, enter into force on December 5, 2026.

Miscellaneous

Special majority requirements
A resolution in accordance with the proposal in item 7 above shall only be valid where supported by no less than two-thirds (2/3) of both the votes cast and the shares represented at the extraordinary general meeting.

Shareholders' right to obtain information
Shareholders are reminded of their right to, at the extraordinary general meeting, obtain information from the board of directors and CEO in accordance with Chapter 7 Section 32 of the Swedish Companies Act. Shareholders who wish to submit questions in advance may do so by post to Surgical Science Sweden AB (publ), att: Hannah Lindgren, Drakegatan 7A, SE-412 50 Gothenburg, Sweden, or via e-mail to agm@surgicalscience.com.

Number of shares and votes
At the time of issuance of this notice, there were a total 51,026,236 shares and votes in Surgical Science Sweden AB, all representing a single class of shares. The company holds no treasury shares.

Documentation
All documentation for resolutions in relation to item 7 is available at the company's offices at Drakegatan 7A in Gothenburg and on the company's website www.surgicalscience.com, no later than three weeks before the extraordinary general meeting. Copies of the documents will be sent to shareholders who so request and who inform the company of their postal address. The documents will also be available at the extraordinary general meeting.

Processing of personal data
For information on how your personal data is processed, please refer to the privacy notice made available at the Euroclear website:
www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammor-engelska.pdf.

Gothenburg, November 2026
Surgical Science Sweden AB (publ)
The board of directors

surgicalscience